Attributable mortality of candidemia at a German tertiary hospital from 1997 to 2001 before the introduction of echinocandins
暂无分享,去创建一个
[1] M. Pirs,et al. Candidaemia in Central Slovenia: A 12‐year retrospective survey , 2021, Mycoses.
[2] D. Marriott,et al. Risk factors for candidaemia: A prospective multi‐centre case‐control study , 2020, Mycoses.
[3] H. Seifert,et al. Attributable mortality of candidemia after introduction of echinocandins , 2020, Mycoses.
[4] M. Hendrickx,et al. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals , 2018, Mycoses.
[5] P. Martín-Dávila,et al. Emerging trends in candidemia: a higher incidence but a similar outcome. , 2012, The Journal of infection.
[6] I. Gould,et al. Epidemiology and management of candidaemia – a retrospective, multicentre study in five hospitals in the UK , 2011, Mycoses.
[7] Elie Azoulay,et al. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study* , 2011, Critical care medicine.
[8] H. Seifert,et al. In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates , 2007, Antimicrobial Agents and Chemotherapy.
[9] R. Wenzel,et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] D. Pittet,et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Sobel,et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] R. Gaynes,et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] A. Tortorano,et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.
[15] H. Richet,et al. Candidemia in French hospitals: incidence rates and characteristics. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[16] L. Saiman,et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] J. Sobel,et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] D. McClish,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] E. Anaissie,et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] D. Snydman,et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. , 1995, Archives of internal medicine.
[21] J. Serody,et al. Intravascular Catheter Exchange and Duration of Candidemia , 1995 .
[22] M. Levenstein,et al. A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .
[23] R F Woolson,et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.
[24] A. Groll,et al. Nosocomial Infections and Multidrug-resistant Organisms in Germany: Epidemiological Data From KISS (The Hospital Infection Surveillance System) , 2011 .
[25] J. Sobel,et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] J. Rex,et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. , 1994, The New England journal of medicine.
[27] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.